[
    {
        "pregunta": "1. What are the key extraarticular conditions that may influence the management of juvenile idiopathic arthritis (JIA), according to the clinical guidelines?",
        "respuesta": "The provided information from the clinical guidelines for juvenile idiopathic arthritis (JIA) specifies that coexisting extraarticular conditions such as uveitis, psoriasis, or inflammatory bowel disease are not addressed within these guidelines. Therefore, the key extraarticular conditions that may influence the management of JIA according to the clinical guidelines are not detailed in the available information.",
        "contexto": [
            "JIA guidelines, these recommendations are for persons already diagnosed as having JIA. 2. Aside from poor prognostic features specified within the recommendations themselves (e.g., specific joints for oligoarthritis, macrophage activation syndrome [MAS]), coexisting extraarticular conditions that would influence disease management, such as uveitis, psoriasis, or inflammatory bowel disease, are not addressed within these guidelines. 3. Recommendations are intended to be used by all clinicians",
            "guidelines. 3. Recommendations are intended to be used by all clinicians caring for persons with JIA and assume that patients do not have contraindications to the recommended pharmacologic treatments. 4. Longer-term glucocorticoid therapy in childhood is not appropriate because of its effects on bone health and growth. Thus, wherever glucocorticoids are suggested, recommended treatment should be limited to the lowest effective dose for the shortest duration possible. 5. Shared decision-making",
            "values, goals, and preferences This guideline breaks new ground in recommending treatment withdrawal for children with systemic JIA, who may have lower risks of flare than are associated with other forms of JIA The low quality of evidence supporting these recommendations underscores the importance of clinical judgment and shared decision-making in everyday care of individuals with JIA. Similarly, this guideline and the many uncertainties acknowledged herein represent a powerful reminder of the",
            "|There is no preferred biologic DMARD.| | | |\n|Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 9. In children with oligoarticular JIA, should poor prognostic features alter the treatment paradigm?|51–52|",
            "|There is no preferred biologic agent.| | | |\n|Consideration of poor prognostic features (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 19. In children with JIA with active TMJ arthritis, should poor prognostic features alter the treatment paradigm?|60|</p>"
        ]
    },
    {
        "pregunta": "2. Why is longer-term glucocorticoid therapy not appropriate in childhood for JIA patients?",
        "respuesta": "Longer-term glucocorticoid therapy is considered inappropriate for patients with juvenile idiopathic arthritis (JIA) in childhood due to its adverse effects on bone health and growth. The recommendations emphasize limiting glucocorticoid treatment to the lowest effective dose for the shortest duration possible to mitigate these negative impacts. The guidelines recognize the potential harms of prolonged glucocorticoid use, including effects on bone growth and overall long-term health outcomes.",
        "contexto": [
            "they can have a rapid onset of action. However, although treatment with high-dose glucocorticoids may be required for disease control, subsequent glucocorticoid therapy should be limited to the lowest effective dosage for the shortest duration possible. Longer-term glucocorticoid therapy in children is not appropriate because of its effects on bone health and growth Systemic JIA with MAS: subsequent therapy (Table 6 Biologic DMARDS or csDMARDs are strongly recommended over long-term",
            "guidelines. 3. Recommendations are intended to be used by all clinicians caring for persons with JIA and assume that patients do not have contraindications to the recommended pharmacologic treatments. 4. Longer-term glucocorticoid therapy in childhood is not appropriate because of its effects on bone health and growth. Thus, wherever glucocorticoids are suggested, recommended treatment should be limited to the lowest effective dose for the shortest duration possible. 5. Shared decision-making",
            "6 Biologic DMARDS or csDMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors. Inactive systemic JIA with or without history of MAS (Table 7 Tapering and discontinuing glucocorticoids is strongly recommended after inactive disease has been attained in systemic JIA. The risk of flare from systemic JIA that is well controlled is considerably outweighed by possible harms from long-term glucocorticoid use, even at",
            "update includes several recommendations against the use of glucocorticoid therapy. These recommendations were made in recognition of the frequent difficulty tapering glucocorticoids leading to undesirable prolonged use and the increasing evidence of the negative impact of glucocorticoids on long-term patient outcomes, including risk for infection, osteoporosis, and cardiovascular disease, in RA and other rheumatic diseases While consensus was easily reached on the majority of statements, 2",
            "|Oral glucocorticoids are conditionally recommended against as part of initial therapy.|Very low|PICO 13. In children with JIA with active TMJ arthritis, should adding oral glucocorticoids to initial therapy be recommended?|58|"
        ]
    },
    {
        "pregunta": "3. What is the recommended approach for shared decision-making when considering treatment options for JIA?",
        "respuesta": "The recommended approach for shared decision-making when considering treatment options for juvenile idiopathic arthritis (JIA) involves engaging families and patients in the decision-making process. This approach emphasizes the importance of considering the values, goals, and preferences of the individuals affected. The guidelines highlight that treatment decisions should follow a shared decision-making process, acknowledging the variety of manifestations and experiences individuals with JIA may present. However, specific details on the implementation of shared decision-making are not provided in the available information.",
        "contexto": [
            "dose for the shortest duration possible. 5. Shared decision-making with families and patients is important when considering treatment options. RESULTS/RECOMMENDATIONS The initial literature review included topics addressed in this report and in the second report https://onlinelibrary.wiley.com/doi/10.1002/ 2 3 4 5 6 7 3 4 5 6 7 Active oligoarthritis (Figure 1 3 Oligoarthritis refers to JIA presenting with involvement of ≤4 joints without systemic manifestations. It may include patients with",
            "guidelines. 3. Recommendations are intended to be used by all clinicians caring for persons with JIA and assume that patients do not have contraindications to the recommended pharmacologic treatments. 4. Longer-term glucocorticoid therapy in childhood is not appropriate because of its effects on bone health and growth. Thus, wherever glucocorticoids are suggested, recommended treatment should be limited to the lowest effective dose for the shortest duration possible. 5. Shared decision-making",
            "values, goals, and preferences This guideline breaks new ground in recommending treatment withdrawal for children with systemic JIA, who may have lower risks of flare than are associated with other forms of JIA The low quality of evidence supporting these recommendations underscores the importance of clinical judgment and shared decision-making in everyday care of individuals with JIA. Similarly, this guideline and the many uncertainties acknowledged herein represent a powerful reminder of the",
            "| Treatment decisions should follow a shared decision-making process. Individuals with rheumatoid arthritis present with a variety of manifestations and experiences. |\n| Optimum rheumatoid arthritis treatment outcomes are achieved through interprofessional teams providing expert patient-centered care. |\n| Recommendations assume no contraindications to listed management strategies. |",
            "|There is no preferred biologic DMARD.| | | |\n|Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 9. In children with oligoarticular JIA, should poor prognostic features alter the treatment paradigm?|51–52|"
        ]
    },
    {
        "pregunta": "4. What is the role of nonsteroidal anti-inflammatory drugs (NSAIDs) in the initial therapy for active oligoarthritis in JIA?",
        "respuesta": "Nonsteroidal anti-inflammatory drugs (NSAIDs) are conditionally recommended as part of the initial therapy for active oligoarthritis in juvenile idiopathic arthritis (JIA). They have traditionally been the cornerstone of treatment for oligoarthritis and can help ease discomfort. However, the initial trial of NSAIDs should be brief due to potential adverse effects, such as gastritis and bruising, and their limited efficacy unless inactive disease is achieved. The guidelines indicate some disagreement among panelists about the appropriate duration of NSAID use before considering therapy escalation, reflecting the need for careful consideration in individual cases.",
        "contexto": [
            "of ≤4 joints without systemic manifestations. It may include patients with different categories of JIA  but who share in common limited numbers of joints involved; guidance for patients with active uveitis, sacroiliitis, or enthesitis can be found in the 2019 guidelines Nonsteroidal antiinflammatory drugs (NSAIDs) A trial of scheduled NSAIDs is conditionally recommended as part of initial therapy for active oligoarthritis. NSAIDs have long been the cornerstone of treatment for oligoarthritis",
            "NSAIDs have long been the cornerstone of treatment for oligoarthritis and can ease discomfort . However, the initial NSAID trial should be brief due to potential adverse effects (e.g., gastritis, bruising) and limited efficacy (unless inactive disease is achieved). Voting panelists could not agree on the appropriate duration of initial use before escalating therapy, as some panelists prefer that the use of NSAIDs be avoided altogether. Glucocorticoids Intraarticular glucocorticoids (IAGCs) are",
            "are several validated disease activity measures for childhood arthritis Treat-to-target approaches have been strongly endorsed for polyarticular JIA Active TMJ arthritis (Figure 2 4 NSAIDs A trial of scheduled NSAIDs is conditionally recommended as part of initial therapy for active TMJ arthritis. NSAIDs have long been the cornerstone of treatment for JIA and can ease discomfort . However, the initial NSAID trial should be brief due to potential adverse effects (e.g., gastritis, bruising) and",
            "<p>|Recommendation|Certainty of evidence|PICO evidence report(s) basis|Page no(s).|\n|---|---|---|---|\n|NSAIDs are conditionally recommended as initial monotherapy.|Very low|PICO 20. In patients with treatment-naive, newly diagnosed systemic JIA without MAS, should non-DMARD treatment (NSAIDs, glucocorticoids) be used as initial therapy?|61–67|\n|Oral glucocorticoids are conditionally recommended against as initial monotherapy.| | | |",
            "In our defined population, we conditionally recommend proceeding to TJA without delay over delaying surgical treatment for a trial of NSAIDs. The NSAIDs are one of the mainstays of nonoperative treatment for OA and can provide pain relief for patients with mild disease. Oral NSAIDs are, however, associated with adverse events (e.g., peptic ulcer disease, acute kidney injury, increased cardiovascular risk, and bleeding) In our defined population, we conditionally recommend proceeding to TJA"
        ]
    },
    {
        "pregunta": "5. Why are intraarticular glucocorticoids strongly recommended as part of initial therapy for active oligoarthritis in JIA?",
        "respuesta": "The clinical guidelines strongly recommend the use of intraarticular glucocorticoids (IAGCs) as part of initial therapy for active oligoarthritis in juvenile idiopathic arthritis (JIA) because of their low potential for adverse effects and high likelihood of sustained response. The guidelines specifically recommend triamcinolone hexacetonide as the preferred agent, despite the evidence being of low quality, due to these advantages.",
        "contexto": [
            "the relative merits of different NSAIDs, there is evidence suggesting that certain agents may have more favorable side effect profiles than others Intraarticular glucocorticoid injections are strongly recommended for patients with knee and/or hip OA and conditionally recommended for patients with hand OA. Trials of intraarticular glucocorticoid injections have demonstrated short-term efficacy in knee OA. Intraarticular glucocorticoid injection is conditionally, rather than strongly, recommended",
            "altogether. Glucocorticoids Intraarticular glucocorticoids (IAGCs) are strongly recommended as part of initial therapy for active oligoarthritis. Triamcinolone hexacetonide is strongly recommended as the preferred agent. Although the evidence is of low quality, IAGCs are strongly recommended due to low potential of adverse effects and high likelihood of sustained response Oral glucocorticoids are conditionally recommended against as part of initial therapy for active oligoarthritis. If, despite",
            "|IAGCs are conditionally recommended as part of initial therapy.|Very low|PICO 12. In children with JIA with active TMJ arthritis, should adding intraarticular glucocorticoids to initial therapy be recommended?|53–57|\n|There is no preferred agent.|Very low|PICO 14. In children with JIA with active TMJ arthritis, should a specific steroid type be recommended for intraarticular injection?|58|",
            "guidelines. 3. Recommendations are intended to be used by all clinicians caring for persons with JIA and assume that patients do not have contraindications to the recommended pharmacologic treatments. 4. Longer-term glucocorticoid therapy in childhood is not appropriate because of its effects on bone health and growth. Thus, wherever glucocorticoids are suggested, recommended treatment should be limited to the lowest effective dose for the shortest duration possible. 5. Shared decision-making",
            "|Oral glucocorticoids are conditionally recommended against as part of initial therapy.|Very low|PICO 13. In children with JIA with active TMJ arthritis, should adding oral glucocorticoids to initial therapy be recommended?|58|"
        ]
    },
    {
        "pregunta": "6. Which conventional synthetic DMARD is conditionally recommended as a preferred agent for JIA patients with inadequate response to NSAIDs and/or intraarticular glucocorticoids?",
        "respuesta": "The provided information indicates that methotrexate (MTX) is conditionally recommended as a preferred conventional synthetic disease-modifying antirheumatic drug (DMARD) for juvenile idiopathic arthritis (JIA) patients with an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs) and/or intraarticular glucocorticoids.",
        "contexto": [
            "recommendation is conditional, as bDMARDs may not always be immediately available, and glucocorticoids may help control systemic and joint manifestations until IL-1 or IL-6 inhibitors can be started. Conventional synthetic DMARDs Conventional synthetic DMARDs are strongly recommended against as initial monotherapy for systemic JIA without MAS. This recommendation is strong despite limited evidence, as the Voting Panel noted multiple small studies of systemic JIA that documented lack of efficacy",
            "for systemic JIA without MAS. Most physicians and patients/caregivers preferred quickly starting IL-1 or IL-6 inhibitors for insufficient response to NSAIDs or glucocorticoids Biologic DMARDs or conventional synthetic DMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors. There is no preferred agent. Given the potential toxicities from long-term use of glucocorticoids Systemic JIA with MAS: initial therapy",
            "|Conventional synthetic DMARDs are strongly recommended for inadequate response to or intolerance of NSAIDs and/or IAGCs.|Very low|PICO 15. In children with JIA with active TMJ arthritis, should DMARD therapies be recommended, and should there be any preferred order of treatment: MTX (subcutaneous and oral), LEF, SSZ, and/or HCQ?|58–59|\n|MTX is conditionally recommended as a preferred agent over LEF.| | | |",
            "|Biologic DMARDs or conventional synthetic DMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors. There is no preferred agent.|Very low|PICO 27. In patients with systemic JIA in whom inactive disease is not achieved despite treatment with both IL-1 and IL-6 agents and/or who are chronically steroid dependent, is long-term stable steroid treatment superior to nonsteroid treatments (cyclophosphamide or",
            "|Biologic DMARDs or conventional synthetic DMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors.|Very low|PICO 27. In patients with systemic JIA in whom inactive disease is not achieved despite treatment with both IL-1 and IL-6 agents and/or who are chronically steroid dependent, is long-term stable steroid treatment superior to nonsteroid treatments (cyclophosphamide or abatacept or rituximab or IVIG or"
        ]
    },
    {
        "pregunta": "7. What is the rationale behind the preference for subcutaneous over oral administration of methotrexate in JIA patients with polyarticular arthritis?",
        "respuesta": "The preference for subcutaneous over oral administration of methotrexate in juvenile idiopathic arthritis (JIA) patients with polyarticular arthritis is conditionally recommended based on the 2019 JIA guidelines. This recommendation was made despite the evidence being of very low quality and primarily because subcutaneous methotrexate has shown superior efficacy compared to oral administration. Additionally, patient preferences may guide the choice of the route of administration.",
        "contexto": [
            "and efficacy in children With regard to the route of administration of methotrexate, the 2019 JIA guidelines conditionally recommended subcutaneous over oral administration for polyarthritis . This recommendation was conditional because the supporting evidence was of very low quality and patient preferences may guide choice of route of administration. There is little reason to suggest that methotrexate should be used differently in oligoarthritis than in polyarthritis. Biologic DMARDs (bDMARDs)",
            "or tsDMARD The recommendation is conditional because the voting panel thought that some patients who have already had persistent disease activity despite use of ≥1 csDMARD will prefer combination treatment for a more rapid response. Recommendations for administration of methotrexate (Table 3) Oral methotrexate is conditionally recommended over subcutaneous methotrexate for patients initiating methotrexate Oral administration is preferred, despite moderate evidence suggesting superior efficacy",
            "|Switching to subcutaneous methotrexate is conditionally recommended over the addition of/switching to alternative DMARD(s) for patients taking oral methotrexate who are not at target.|Very low|PICO 18|p. 235|</p>",
            "is preferred, despite moderate evidence suggesting superior efficacy of subcutaneous injections, due to the ease of oral administration and similar bioavailability at typical starting doses Initiation/titration of methotrexate to a weekly dose of at least 15 mg within 4 to 6 weeks is conditionally recommended over initiation/ titration to a weekly dose of <15 mg The recommendation is conditional because there are few studies comparing different dosing strategies and wide variation in physician",
            "24 hours or weekly subcutaneous injections, and/or an increased dose of folic/folinic acid, is conditionally recommended over switching to alternative DMARD(s) for patients not tolerating oral weekly methotrexate Despite the very low certainty of evidence supporting these strategies for alleviating side effects related to methotrexate, split dosing, changing to the subcutaneous route of administration, and increased doses of folic/folinic acid are the preferred initial strategies over switching"
        ]
    },
    {
        "pregunta": "8. When should biologic DMARDs be strongly recommended for JIA patients with inadequate response to NSAIDs and/or conventional synthetic DMARDs?",
        "respuesta": "Biologic disease-modifying antirheumatic drugs (DMARDs) are strongly recommended for juvenile idiopathic arthritis (JIA) patients who have an inadequate response to or intolerance of nonsteroidal anti-inflammatory drugs (NSAIDs) and/or intraarticular glucocorticoids (IAGCs) and at least one conventional synthetic DMARD (csDMARD). There is no preferred biologic DMARD for this scenario. This recommendation is based on the potential for biologic DMARDs to yield rapid and sustained improvement in JIA.",
        "contexto": [
            "|Biologic DMARDs are strongly recommended if there is inadequate response to or intolerance of NSAIDs and/or IAGCs and at least 1 conventional synthetic DMARD.|Very low|PICO 6. In children with oligoarticular JIA, should biologic therapies be recommended, and should there be any preferred order of treatment: TNFi treatment, biologic treatments with other mechanisms of action?|42–47|\n|There is no preferred biologic DMARD.| | | |",
            "in oligoarthritis than in polyarthritis. Biologic DMARDs (bDMARDs) Biologic DMARDs are strongly recommended if there is inadequate response to or intolerance of NSAIDs and/or IAGCs and at least 1 csDMARD for active oligoarthritis. There is no preferred bDMARD. Biologic DMARDs are preferred over combining csDMARDs or switching to a different csDMARD, due to a greater likelihood that bDMARDs will yield rapid and sustained improvement in JIA Although tumor necrosis factor inhibitors (TNFi) are the",
            "recommendation is conditional, as bDMARDs may not always be immediately available, and glucocorticoids may help control systemic and joint manifestations until IL-1 or IL-6 inhibitors can be started. Conventional synthetic DMARDs Conventional synthetic DMARDs are strongly recommended against as initial monotherapy for systemic JIA without MAS. This recommendation is strong despite limited evidence, as the Voting Panel noted multiple small studies of systemic JIA that documented lack of efficacy",
            "for systemic JIA without MAS. Most physicians and patients/caregivers preferred quickly starting IL-1 or IL-6 inhibitors for insufficient response to NSAIDs or glucocorticoids Biologic DMARDs or conventional synthetic DMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors. There is no preferred agent. Given the potential toxicities from long-term use of glucocorticoids Systemic JIA with MAS: initial therapy",
            "|Biologic DMARDs or conventional synthetic DMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors.|Very low|PICO 27. In patients with systemic JIA in whom inactive disease is not achieved despite treatment with both IL-1 and IL-6 agents and/or who are chronically steroid dependent, is long-term stable steroid treatment superior to nonsteroid treatments (cyclophosphamide or abatacept or rituximab or IVIG or"
        ]
    },
    {
        "pregunta": "9. Why is formal assessment of disease activity using validated measures conditionally recommended for JIA patients?",
        "respuesta": "The formal assessment of disease activity using validated measures is conditionally recommended for patients with juvenile idiopathic arthritis (JIA) to guide treatment decisions. This is especially important for facilitating treat-to-target approaches. The use of validated disease activity measures can help in the systematic assessment of a patient's condition, ensuring that treatment is tailored according to the specific disease features, joint involvement, and response to therapy. Such measures also help in making informed decisions about adjusting treatment plans to achieve and maintain disease remission or low disease activity, thus optimizing outcomes for patients with JIA.",
        "contexto": [
            "to guide treatment decisions. Use of validated disease activity measures is conditionally recommended to guide treatment decisions, especially to facilitate treat-to-target approaches. Treatment for oligoarthritis can and should be modified based on the involvement of specific joints or disease features Voting panelists conditionally recommended formal assessment of disease activity using validated measures. There are several validated disease activity measures for childhood arthritis",
            "|Use of validated disease activity measures is conditionally recommended to guide treatment decisions, especially to facilitate treat-to-target approaches.|Very low|PICO 10. In children with oligoarticular JIA, should disease activity measures alter the treatment paradigm?|52|</p>",
            "are several validated disease activity measures for childhood arthritis Treat-to-target approaches have been strongly endorsed for polyarticular JIA Active TMJ arthritis (Figure 2 4 NSAIDs A trial of scheduled NSAIDs is conditionally recommended as part of initial therapy for active TMJ arthritis. NSAIDs have long been the cornerstone of treatment for JIA and can ease discomfort . However, the initial NSAID trial should be brief due to potential adverse effects (e.g., gastritis, bruising) and",
            "of disease activity using validated measures to reach a predefined target. Moreover, 1) the number of remaining available treatment options, 2) the impact of noninflammatory causes of pain, comorbidities, and/or damage on the accuracy of validated disease activity assessments, and 3) the patient's threshold for changing medications may have a more significant influence on the decision to follow a treat-to-target approach in this population compared to patients who are bDMARD-and tsDMARD-naive.",
            "JIA guidelines, these recommendations are for persons already diagnosed as having JIA. 2. Aside from poor prognostic features specified within the recommendations themselves (e.g., specific joints for oligoarthritis, macrophage activation syndrome [MAS]), coexisting extraarticular conditions that would influence disease management, such as uveitis, psoriasis, or inflammatory bowel disease, are not addressed within these guidelines. 3. Recommendations are intended to be used by all clinicians"
        ]
    },
    {
        "pregunta": "10. What is the recommended initial therapy for systemic JIA without macrophage activation syndrome (MAS) according to the guidelines?",
        "respuesta": "The guidelines for systemic juvenile idiopathic arthritis (JIA) without macrophage activation syndrome (MAS) conditionally recommend the use of biologic DMARDs, specifically IL-1 and IL-6 inhibitors, as initial monotherapy. These inhibitors are considered extremely effective and well-tolerated treatments for systemic JIA and have been rapidly adopted in clinical practice. There is no preferred agent among the biologic DMARDs for this condition. Conventional synthetic DMARDs are strongly recommended against as initial monotherapy for systemic JIA without MAS, while oral glucocorticoids are also conditionally recommended against as initial monotherapy, though they may be used temporarily to control symptoms until biologic DMARDs are available.",
        "contexto": [
            "bDMARD because current studies of TMJ arthritis have been small and observational Systemic JIA with and without MAS (Figure 3 Systemic JIA without MAS: initial therapy (Table 5) Biologic DMARDs Biologic DMARDS (IL-1 and IL-6 inhibitors) are conditionally recommended as initial monotherapy for systemic JIA without MAS. There is no preferred agent. IL-1 and IL-6 inhibitors are extremely effective and welltolerated treatments for systemic JIA  and have been rapidly adopted in clinical practice",
            "multiple small studies of systemic JIA that documented lack of efficacy at controlling systemic features that are typically present at onset of disease, leading to a continued need for glucocorticoids Systemic JIA without MAS: subsequent therapy (Table 5 IL-1 and IL-6 inhibitors are strongly recommended over a single or combination of csDMARDs for inadequate response to or intolerance of NSAIDs and/or glucocorticoids for systemic JIA without MAS. Most physicians and patients/caregivers",
            "JIA guidelines, these recommendations are for persons already diagnosed as having JIA. 2. Aside from poor prognostic features specified within the recommendations themselves (e.g., specific joints for oligoarthritis, macrophage activation syndrome [MAS]), coexisting extraarticular conditions that would influence disease management, such as uveitis, psoriasis, or inflammatory bowel disease, are not addressed within these guidelines. 3. Recommendations are intended to be used by all clinicians",
            "proportion of patients with systemic JIA will respond to NSAIDs alone Glucocorticoids Oral glucocorticoids are conditionally recommended against as initial monotherapy for systemic JIA without MAS. In most cases, oral glucocorticoids should not be used as initial monotherapy in patients with systemic JIA without MAS and, if used, should be limited to the lowest effective dosage for the shortest duration possible. This recommendation is conditional, as bDMARDs may not always be immediately",
            "recommendation is conditional, as bDMARDs may not always be immediately available, and glucocorticoids may help control systemic and joint manifestations until IL-1 or IL-6 inhibitors can be started. Conventional synthetic DMARDs Conventional synthetic DMARDs are strongly recommended against as initial monotherapy for systemic JIA without MAS. This recommendation is strong despite limited evidence, as the Voting Panel noted multiple small studies of systemic JIA that documented lack of efficacy"
        ]
    }
]